This Article Full Text Full Text (PDF) Supplementary data and color version of Fig. 3 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Syljuåsen, R. G. Articles by Bartek, J. Search for Related Content PubMed PubMed Citation Articles by Syljuåsen, R. G. Articles by Bartek, J.

Inhibition of Chk1 by CEP-3891 Accelerates Mitotic Nuclear Fragmentation in Response to Ionizing Radiation

¹ Department of Cell Cycle and Cancer and ² Apoptosis Laboratory, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark

The human checkpoint kinase Chk1 has been suggested as a target for cancer treatment. Here, we show that a new inhibitor of Chk1 kinase, CEP-3891, efficiently abrogates both the ionizing radiation (IR)-induced S and G₂ checkpoints. When the checkpoints were abrogated by CEP-3891, the majority (64%) of cells showed fragmented nuclei at 24 hours after IR (6 Gy). The formation of nuclear fragmentation in IR-treated human cancer cells was directly visualized by time-lapse video microscopy of U2-OS cells expressing a green fluorescent protein-tagged histone H2B protein. Nuclear fragmentation occurred as a result of defective chromosome segregation when irradiated cells entered their first mitosis, either prematurely without S and G₂ checkpoint arrest in the presence of CEP-3891 or after a prolonged S and G₂ checkpoint arrest in the absence of CEP-3891. The nuclear fragmentation was clearly distinguishable from apoptosis because caspase activity and nuclear condensation were not induced. Finally, CEP-3891 not only accelerated IR-induced nuclear fragmentation, it also increased the overall cell killing after IR as measured in clonogenic survival assays. These results demonstrate that transient Chk1 inhibition by CEP-3891 allows premature mitotic entry of irradiated cells, thereby leading to accelerated onset of mitotic nuclear fragmentation and increased cell death.

This article has been cited by other articles:

				M. S. Luijsterburg, C. Dinant, H. Lans, J. Stap, E. Wiernasz, S. Lagerwerf, D. O. Warmerdam, M. Lindh, M. C. Brink, J. W. Dobrucki, et al. Heterochromatin protein 1 is recruited to various types of DNA damage J. Cell Biol., May 18, 2009; 185(4): 577 - 586. [Abstract] [Full Text] [PDF]

				E. J. Chung, A. P. Brown, H. Asano, M. Mandler, W. E. Burgan, D. Carter, K. Camphausen, and D. Citrin In vitro and In vivo Radiosensitization with AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase Clin. Cancer Res., May 1, 2009; 15(9): 3050 - 3057. [Abstract] [Full Text] [PDF]

				J. M. R. Danielsen, D. H. Larsen, K. B. Schou, R. Freire, J. Falck, J. Bartek, and J. Lukas HCLK2 Is Required for Activity of the DNA Damage Response Kinase ATR J. Biol. Chem., February 13, 2009; 284(7): 4140 - 4147. [Abstract] [Full Text] [PDF]

				J. M. Leonard, H. Ye, C. Wetmore, and L. M. Karnitz Sonic Hedgehog signaling impairs ionizing radiation-induced checkpoint activation and induces genomic instability J. Cell Biol., November 3, 2008; 183(3): 385 - 391. [Abstract] [Full Text] [PDF]

				M. A. Morgan, L. A. Parsels, J. Maybaum, and T. S. Lawrence Improving Gemcitabine-Mediated Radiosensitization Using Molecularly Targeted Therapy: A Review Clin. Cancer Res., November 1, 2008; 14(21): 6744 - 6750. [Abstract] [Full Text] [PDF]

				B. Rebacz, T. O. Larsen, M. H. Clausen, M. H. Ronnest, H. Loffler, A. D. Ho, and A. Kramer Identification of Griseofulvin as an Inhibitor of Centrosomal Clustering in a Phenotype-Based Screen Cancer Res., July 1, 2007; 67(13): 6342 - 6350. [Abstract] [Full Text] [PDF]

				A. N. Tse, R. Carvajal, and G. K. Schwartz Targeting Checkpoint Kinase 1 in Cancer Therapeutics Clin. Cancer Res., April 1, 2007; 13(7): 1955 - 1960. [Abstract] [Full Text] [PDF]

				L. Carlessi, G. Buscemi, G. Larson, Z. Hong, J. Z. Wu, and D. Delia Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2 Mol. Cancer Ther., March 1, 2007; 6(3): 935 - 944. [Abstract] [Full Text] [PDF]

				A. N. Tse, K. G. Rendahl, T. Sheikh, H. Cheema, K. Aardalen, M. Embry, S. Ma, E. J. Moler, Z. J. Ni, D. E. Lopes de Menezes, et al. CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo Clin. Cancer Res., January 15, 2007; 13(2): 591 - 602. [Abstract] [Full Text] [PDF]

				R. G. Syljuasen, S. Jensen, J. Bartek, and J. Lukas Adaptation to the Ionizing Radiation-Induced G2 Checkpoint Occurs in Human Cells and Depends on Checkpoint Kinase 1 and Polo-like Kinase 1 Kinases Cancer Res., November 1, 2006; 66(21): 10253 - 10257. [Abstract] [Full Text] [PDF]

				S. Liu, S. Bekker-Jensen, N. Mailand, C. Lukas, J. Bartek, and J. Lukas Claspin Operates Downstream of TopBP1 To Direct ATR Signaling towards Chk1 Activation. Mol. Cell. Biol., August 1, 2006; 26(16): 6056 - 6064. [Abstract] [Full Text] [PDF]

				C. J. Lord, M. D. Garrett, and A. Ashworth Targeting the Double-Strand DNA Break Repair Pathway as a Therapeutic Strategy Clin. Cancer Res., August 1, 2006; 12(15): 4463 - 4468. [Abstract] [Full Text] [PDF]

				S. Bekker-Jensen, C. Lukas, R. Kitagawa, F. Melander, M. B. Kastan, J. Bartek, and J. Lukas Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks J. Cell Biol., April 24, 2006; 173(2): 195 - 206. [Abstract] [Full Text] [PDF]

				M. S. Ricci and W.-X. Zong Chemotherapeutic approaches for targeting cell death pathways. Oncologist, April 1, 2006; 11(4): 342 - 357. [Abstract] [Full Text] [PDF]

				D. Sampath, J. Cortes, Z. Estrov, M. Du, Z. Shi, M. Andreeff, V. Gandhi, and W. Plunkett Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial Blood, March 15, 2006; 107(6): 2517 - 2524. [Abstract] [Full Text] [PDF]

				S. Bekker-Jensen, C. Lukas, F. Melander, J. Bartek, and J. Lukas Dynamic assembly and sustained retention of 53BP1 at the sites of DNA damage are controlled by Mdc1/NFBD1 J. Cell Biol., July 18, 2005; 170(2): 201 - 211. [Abstract] [Full Text] [PDF]

				R. G. Syljuasen, C. S. Sorensen, L. T. Hansen, K. Fugger, C. Lundin, F. Johansson, T. Helleday, M. Sehested, J. Lukas, and J. Bartek Inhibition of Human Chk1 Causes Increased Initiation of DNA Replication, Phosphorylation of ATR Targets, and DNA Breakage Mol. Cell. Biol., May 1, 2005; 25(9): 3553 - 3562. [Abstract] [Full Text] [PDF]

				L. M. Karnitz and S. J. H. Arlander Chk1, a Novel Target to Sensitize Tumor Cells to Replication Inhibitors Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 254 - 257. [Full Text] [PDF]